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Abstract To gain insight into the nature of the lecithin-
cholesterol acyltransferase inhibitory factor(s), we separated
and collected the oxidation products from oxidized lipoproteins
after lipoxygenase treatment. Isolated fractions identified by
chemiluminescence, as hydroperoxides of phosphatidylcholine,
were found to produce a significant reduction of lecithin-
cholesterol acyltransferase activity. The reaction kinetics of
lecithin-cholesterol acyltransferase with reconstitued high density
lipoproteins were studied in the presence of 0.6 and 1.2 WM
hydroperoxides of phosphatidylcholine. No significant changes in
the apparent Vmax were observed but a concentration-dependent
increase in slope of the reciprocal plots and in the apparent Km
values was observed with increasing hydroperoxide concentra-
tions. These results show that the active site of lecithin-
cholesterol acyltransferase is not affected by the presence of
phosphatidylcholine hydroperoxides. Nevertheless, hydroperox-
ides of phosphatidylcholine altered the reactivity of lecithin-
cholesterol acyltransferase for reconstitued high density lipopro-
teins suggesting either an alteration of the binding of lecithin-
cholesterol acyltransferase to the reconstitued high density
lipoproteins or a competitive inhibition mechanism.
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1. Introduction
It is now generally believed that the oxidative modi¢cations
of plasma lipoproteins enhance their atherogenicity [1]. Oxi-
dized low density lipoproteins (LDL) are taken up by the
scavenger receptor mechanism, resulting in cholesterol accu-
mulation and subsequent foam cell formation. High density
lipoproteins (HDL) serve a protective role in inhibiting the
progression of atherosclerosis. First, HDL play a crucial
role in the removal of cholesterol from peripheral tissues
and its transfer to the liver [2]. Secondly, HDL protect LDL
from oxidative damage, possibly through the exchange of oxi-
dized phospholipids (PL) from LDL to HDL or through com-
petitive oxidation between HDL and LDL phospholipids [3].
However, lipid peroxidation products carried on HDL
could impair the ability of HDL to promote cholesterol e¥ux
[4] and lecithin-cholesterol acyl transferase (LCAT) activation
[5], two key processes in the reverse cholesterol transport.
Recently, Bielicki et al. [6] have observed that minimally
oxidized LDL were potent inhibitors of the LCAT activity
and they supposed that the inhibition was due to a lipophilic
oxidation product. Moreover, Subbaiah and Liu [7] showed
that LCAT activity was inactivated by polar phospholipids
containing short chain acyl groups at the sn-2 position (short
chain polar phosphatidylcholine), which were produced dur-
ing phospholipid peroxidation by chain fragmentation of
phosphatidylcholine hydroperoxide derivatives.
We used a high performance liquid chromatography
(HPLC) procedure to separate and collect the oxidation prod-
ucts from oxidized lipoproteins. To clarify the role of these
products in the inhibition of LCAT, we prepared reconstitued
HDL (rHDL). This substrate consists of the mixture of egg-
phosphatidylcholine (egg-PC), cholesterol and puri¢ed apoli-
poprotein A-I (apoA-I). We studied the reaction kinetics of
LCAT with the rHDL in the presence of isolated fractions of
oxidized PL.
2. Materials and methods
HPLC grade solvents and analytical grade chemicals were from
Carlo Erba (Milano, Italy) or from Merck (Darmstadt, Germany).
Microperoxidase, isoluminol (6-amino-2,3-dihydro-1,4-phthalazine-
dione) and soybean lipoxygenase (type IB, EC 1 13 11 12), egg-PC,
cholesterol and defatted bovine serum albumin were from Sigma (St.
Louis, MO, USA). Nordihydroguaiaretic acid (NDGA) was from
TEBU-Biomol (USA).
2.1. Chromatographic equipment
The HPLC equipment (Thermo Separation Products, Les Ulis,
France) included an automatic injector with a 200 Wl sample loop, a
250U4.6 mm C18 and a 150U4.6 mm C8 Kromasil 5 Wm (Touzart et
Matignon, Les Ulis, France) analytical columns and a UV-visible light
detector (Thermo Separation Products, Les Ulis, France). The £uoro-
meter (Spectro£ow 980 £uorescence detector, Applied Biosystems,
Ramsey, NJ, USA) was equipped with a 5 Wl £ow cell.
2.2. Isolation of LDL from human plasma
Blood was collected from healthy individuals into tubes containing
EDTA (Becton Dickinson, Rutherford, NJ, USA) and samples were
chilled to 4‡C. Plasma was obtained after low speed centrifugation
(1000Ug) to remove blood cells. Low density lipoproteins (LDL,
d 1.019^1.063 g/ml) were isolated by preparative, sequential ultracen-
trifugation [8] and dialyzed (at 4‡C) against 10 mM Tris-HCl, pH 7.4,
containing 0.15 M NaCl.
2.3. LDL oxidation
Oxidation of LDL (1.6 g/l LDL phospholipids) was performed with
soybean lipoxygenase (type IB, EC 1 13 11 12, Sigma, St. Louis, MO,
USA), dissolved in 0.1 M borate bu¡er, pH 9.2, (400 mg/l). The
mixture was incubated with gentle shaking at 37‡C for 16 h. The
oxidation was stopped by addition of NDGA (60 WM).
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2.4. Isolation of oxidized phospholipid products
The major products of lipid oxidation were isolated for their sub-
sequent analysis as potential substrates for LCAT inhibition. For this
purpose, the lipids were extracted from oxidized LDL. Hydroperox-
ides from free fatty acids, PC and cholesterol ester (CE), short chain
polar phosphatidylcholine and non-oxidized molecular species from
PC and CE were extracted with methanol and hexane (2:10, v/v).
The mixture was partitioned between the hexane layer (upper phase
containing CE) and the methanol/water layer (lower phase containing
PL and free fatty acids). These layers were separated by centrifugation
at 1500Ug for 5 min. The two layers were collected and evaporated to
dryness under a nitrogen stream. The dried lipid residues were then
dissolved in 200 Wl methanol and injected into the HPLC system.
Phospholipid separation was done using two serial analytical columns,
a C8 (150U4.6 mm) and a C18 (250U4.6 mm) Kromasil 5 Wm, main-
tained at 40‡C. The mobile phase was 6% 10 mM ammonium acetate,
pH 5 and 94% methanol (£ow rate 1.5 ml/min) as previously described
by Laureaux et al. [9]. Cholesteryl ester separation was performed
with a 250U4.6 mm C18 Kromasil column, the mobile phase was
100% methanol. Molecular species of PL and CE were detected at
205 nm and the eluate was then mixed with the chemiluminescence
reagent prepared as described by Yamamoto et al. [10] with slight
modi¢cations (55 mg/l isoluminol dissolved in 0.1 M borate bu¡er,
pH 9.2 and 10 mg/l microperoxidase) to speci¢cally quantify hydro-
peroxides from PC, CE and free fatty acids (£ow rate 1 ml/min). The
solution was passed through a £uorometer used as a photon detector
with the excitation source turned o¡. Identi¢cation of molecular spe-
cies of PC and CE and their corresponding hydroperoxides was real-
ized as previously described by Therond et al. [11]. From each extract
of lipoxygenase-oxidized LDL, three fractions of oxidized lipids were
obtained after the HPLC separation and collected in glass vials. The
solvent was evaporated under a gentle stream of nitrogen. Each frac-
tion from PC and CE was redissolved in 250 Wl methanol and kept
frozen at 375‡C until use.
2.5. Puri¢cation of apoA-I and LCAT
Human apoA-I used in the preparation of the complexes was pu-
ri¢ed from plasma of healthy donors as previously described by us
[12]. LCAT was puri¢ed as previously described from 1 l of human
serum [13].
2.6. Preparation of discoidal apoA-I-egg-PC-cholesterol complexes
used as a substrate for the LCAT activity measurement
The activity of LCAT was assessed using a synthetic substrate that
consisted of recombinant complexes of apoA-I with egg-PC and chol-
esterol that were formed using the sodium cholate dialysis procedure
of Matz and Jonas [14]. ApoA-I:egg-PC:cholesterol molar ratios of
1:120:6 (initial ratio) were used assuming a molecular weight of
28 000, 780 and 387 for apoA-I, egg-PC and cholesterol, respectively.
Radiolabelled [3H]cholesterol (Amersham, Les Ulis, France) was in-
corporated into the particle preparation at a ratio of 2 WCi/WM of
cholesterol. The diameters of rHDL were estimated by non-denatur-
ing 8^25% polyacrylamide gradient gel electrophoresis (Pharmacia
PHAST gradient gel electrophoresis).
2.7. LCAT reaction kinetics
Initial velocity (Vo) determinations of enzymatic activity were per-
formed in capped glass tubes. The incubation mixtures contained 1.5^
36 nmol of cholesterol in complexes with apoA-I and egg-PC, 2 mg of
defatted bovine serum albumin, 4 mM mercaptoethanol, 1.25 U of
LCAT activity (1 unit=1 nmol of cholesterol ester (CE) formed/h) in a
¢nal volume of 0.5 ml of 1 mM EDTA, 1 mM NaN3, 10 mM Tris-
HCl bu¡er, pH 7.4. 5 or 10 Wl of each isolated fraction containing
oxidized lipids dissolved in methanol, were mixed with the reaction
mixture and incubated at 37‡C in a metabolic shaker during 1 h to
assay the LCAT activity. The reactions were stopped and the lipids
were extracted with chloroform/methanol (2/1, v/v) according to the
procedure of Folch et al. [15]. Carrier cholesterol and CE (V100 Wg
each) were added to the organic solution of the lipids prior to drying.
CE was separated from unesteri¢ed cholesterol using thin layer silicic
acid chromatography and was quanti¢ed by scintillation counting.
Results were expressed as nmol CE formed per h. Under our condi-
tions, less than 20% of the cholesterol was esteri¢ed, ensuring that
initial velocity values were being measured. Determination of the ap-
parent maximal initial velocity (app Vmax) and apparent Michaelis-
Menten constant (app Km) was performed using a Lineweaver-Burk
plot of the kinetic data.
3. Results
To identify the nature of the inhibitor for the LCAT reac-
tion produced during lipid peroxidation, we extracted lipids
from oxidized LDL and we separated the oxidized phospho-
lipids and sterol fractions on a reverse phase HPLC. When
incubated with the reaction mixture to assay the LCAT activ-
ity, none of the sterol fractions recovered in the hexane layer,
produced a reduction in the LCAT activity after 1 h of in-
cubation (data not shown).
Fig. 1 shows the HPLC patterns from phospholipids extract
monitored by UV absorption at 205/234 nm before and after
lipoxygenase treatment (respectively Fig. 1A and B). Fig. 1C
shows the speci¢c detection (after mixing with the chemilumi-
nescence reagent) of hydroperoxides corresponding to the
peaks absorbing at 234 nm. Three major fractions were col-
lected. These fractions were characterized by their retention
times, their UV light absorption and their chemiluminescence
detection. Fraction I, eluted between 0 and 4 min, presented a
strong absorption at 234 nm and was detected by the chem-
iluminescence system. This fraction was identi¢ed as free fatty
acid hydroperoxides coming from linoleic acid or arachidonic
acid (13 (S) HPODE and 15 (S) HPETE, respectively). Frac-
tion II (elution time between 4 and 9 min), contained peaks
which absorbed at 234 nm but were not detectable by the
chemiluminescence reaction. We could speculate that this frac-
tion contained short chain polar PC (e.g. esteri¢ed conjugated
enols at the sn-2 position) resulting from the chain fragmen-
tation of PC hydroperoxides. Fraction III, eluted between 9
and 22 min, contained peaks which strongly absorbed at 234
nm and were detectable by the chemiluminescence reaction.
These peaks were identi¢ed as the hydroperoxides coming
from 16:0-18:2, 16:0-20:4, 16:0-22:6 PC and 18:0-18:2,
18:0-20:4, 18:0-22:6 PC (PCOOH).
When incubated with the reaction mixture to assay LCAT
activity, only the fraction III, corresponding to PCOOH, led to
a 40% decrease in the LCAT activity after 1 h of incubation.
For the study of the activity of LCAT in the presence of
PCOOH, we used a synthetic substrate (rHDL). The size of
the rHDL was showed to be monodispersed and centered
around 98 Aî . The molar composition of these complexes
was determined and the ¢nal composition of apoA-I:egg-
PC:cholesterol was V1:99:4.
Fig. 2 shows the Lineweaver-Burk plots for the LCAT re-
action with rHDL in the absence or in the presence of
PCOOH. The maximal initial velocity (Vmax) was not a¡ected
by the presence of 0.6 Wmol/l of PCOOH but we observed an
increase of the app Km from 1.5U1036 M to 2.4U1036 M. In
the presence of 1.2 WM PCOOH, the app Km increased to
4.2U1036 M and furthermore, we observed a small decrease
of the Vmax from 1 nmol CE/h to 0.93 nmol CE/h. We also
determined an apparent inhibition constant Ki (Ki = 5U1037
M) using the following equation app K’m = app KmU(1+[I]/
Ki) (see the insert in Fig. 2). In this expression, Km is the
apparent Michaelis constant in the absence of the inhibitor,
K’m is the apparent Michaelis constant in the presence of
di¡erent inhibitor concentrations, [I] is the inhibitor concen-
tration, Ki is the apparent dissociation constant of the en-
zyme-inhibitor complex.
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4. Discussion
Two recent studies have reported the inhibitory e¡ect of
lipoperoxidation products on the LCAT activity. Bielicki et
al. [6] have observed that a lipophilic oxidation product, con-
tained in minimally oxidized LDL, inhibited the LCAT activ-
ity. Subbaiah et Liu [7] have reported that the short chain
polar PC, produced during lipoperoxidation, could inhibit
the cholesterol esteri¢cation by modifying the interfacial bind-
ing domain of LCAT. In our study, we have extracted phos-
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Fig. 1. HPLC elution pro¢le of phospholipid molecular species and their corresponding hydroperoxides in LDL before lipoxygenase treatment
(A) and after lipoxygenase treatment (B) using two serial Kromasil C8 and C18 analytical columns at 40‡C. The mobile phase was 6% 10 mM
ammonium acetate, pH 5 and 94% methanol (£ow rate 1.5 ml/min). Eluates were monitored by UV absorbance at 234 nm until 22 min to de-
tect conjugated dienes and then at 205 nm to detect the fatty acid molecular species. Hydroperoxides were identi¢ed with the chemilumines-
cence reagent (C). The numbered peaks represent (1) PC 16:0/22:6, (2) PC 16:0/20:4, (3) PC 16:0/18:2, (4) PC 18:0/22:6, (5) PC 18:0/20:4, (6)
PC 18:0/18:2. Peak 7 containing free fatty acid hydroperoxides (mainly linoleic acid hydroperoxide) was fraction I. Fraction II contained short
chain polar PC as tentatively identi¢ed by Subbaiah et al. [7], based on their chromatographic behavior. Peak 8 contained PCOOH 16:0/18:2,
peak 9 contained two PCOOH compounds identi¢ed as PCOOH 16:0/20:4 and PCOOH 16:0/22:6, peak 10 contained PCOOH 18:0/18:2 and
peak 11 contained PCOOH 18:0/20:4+18:0/22:6, they were collected together as fraction III. 16:0/18:2 PC, 1-palmitoyl-2-linoleoyl-sn-glycero-3-
phosphocholine; 16:0/20:4 PC, 1-pamitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine; 16:0/22:6 PC, 1-pamitoyl-2-docosahexaenoyl-sn-glycero-
3-phosphocholine; 18:0/18:2 PC, 1-stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine; 18:0/20:4 PC, 1-stearoyl-2-arachidonoyl-sn-glycero-3-phos-
phocholine; 18:0/22:6 PC, 1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phospho-choline.
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pholipids from oxidized LDL and we have isolated among the
polar products of oxidized phospholipids those presenting free
fatty acids with a hydroperoxide function, short chain polar
PC and PC with a hydroperoxide function on the poly-unsat-
urated fatty acid located at the sn-2 position of PC. With the
lipoxygenase treatment, PCOOH were mainly produced while
the other more polar products such as free fatty acid hydro-
peroxides and short chain polar PC were poorly produced.
Moreover, among the fractions isolated from oxidized lipids,
only the fraction with PCOOH produced a signi¢cant inhib-
ition in the LCAT activity.
We examined the reactivity of rHDL particles with LCAT
to investigate the e¡ects of the PCOOH on LCAT reaction
kinetics.
The reaction of LCAT with rHDL involves multiple steps:
the association of LCAT with lipid interface, followed by
activation by apolipoproteins, binding of lipid substrate(s)
to the active site and subsequent catalytic events. LCAT uti-
lizes phospholipids and unesteri¢ed cholesterol for cholesterol
ester formation on HDL. The active site of LCAT contains a
catalytic triad of aspartic acid, histidine and serine residues
[16,17]. Although the three dimensional structure of LCAT
has not been determined, the presence of separate catalytic
and interfacial domains may be inferred for this enzyme
[16,18,19]. The possible roles of PCOOH are re£ected in the
kinetic parameters of the LCAT reaction.
As the Vmax was weakly changed by the presence of in-
creased PCOOH concentrations, we could conclude that
PCOOH did not modify amino acids in the active site of
the enzyme. On the other hand, we observed changes in the
slopes of the Lineweaver-Burk plots (Fig. 2) and app Km with
increasing PCOOH concentrations. Many factors, size, mor-
phology, phospholipid composition and apolipoprotein com-
position, have been shown to modulate the LCAT activity
when substrate analogs such as proteoliposomes or rHDL
are used [16]. The close interrelation of all these factors makes
it di⁄cult to examine one of these parameters. In the present
work, by using rHDL of a de¢ned composition and by the
introduction of a very low amount of PCOOH during the
incubation, we avoided major changes in the particle size
and total phospholipid content and therefore in the confor-
mation of apoA-I. We observed changes in the slopes of the
Lineweaver-Burk plots (Fig. 2) and app Km with increasing
PCOOH concentrations suggesting that PCOOH compete
with PC for the active site or alter the binding of LCAT to
the rHDL surface. Indeed, due to the hydrophilic nature of
the hydroperoxides, PCOOH may have direct access to the
active site of LCAT and act as a competitor with PC mole-
cules. The variations in app K’m values could also re£ect, as
previously reported by Bolin and Jonas [20,21], the a⁄nity of
LCAT for rHDL. However, whatever the substrate concen-
tration used in this work, the inhibitor concentration in the
interface represents less than 1% molar ratio PCOOH/PC.
Thus, the addition of PCOOH does not change the interfacial
lipid composition of the rHDL and cannot a¡ect signi¢cantly
the binding of the LCAT to the lipid interface. Nevertheless,
we have also to take into account that PCOOH could react
with a domain of LCAT that is involved in the interfacial
recognition or with a domain of apoA-I that is implicated
in the interfacial binding with the enzyme. Indeed, on the
one hand, PCOOH could modify the free cysteine residues
of LCAT [22] or could react with the free amino group of
proteins as previously reported by Fruebis et al. [23] and lead
to the formation of Schi¡ base or cross-linking of proteins.
On the other hand, Garner et al. have recently reported [24]
the role for methionine residues of apoA-I and apoA-II in
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Fig. 2. Lineweaver-Burk plots of LCAT reaction kinetics with rHDL in the presence of increasing concentrations of the inhibitor in the me-
dium. PCOOH were incubated at a ¢nal concentration of 0.6 WM or 1.2 WM, for 1 h, with the reaction mixture to assay the LCAT activity
(37‡C). Vo is the initial reaction velocity measured at 37‡C. All data are expressed as mean þ S.D. of triplicate samples. When not shown, the
S.D. is smaller than the size of the symbols. The insert shows the variation of apparent K’m with PCOOH concentrations in order to obtain
the inhibition constant, Ki.
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reducing PCOOH to PC hydroxides. As the Met residues are
located within the known lipid binding domains of these apo-
lipoproteins, the oxidation of Met residues of apoA-I could
a¡ect their ability to interact with lipids, which is crucial for
activation of LCAT. Thus, the inhibition of LCAT obtained
with PCOOH could be linked to oxidative modi¢cations of
apoA-I and this possibility could also explain the results of
Bielicki et al. [6] which reported cross-linking of apoA-I mol-
ecules induced by copper-oxidized LDL associated with a re-
duced LCAT activity.
Our study con¢rms that LCAT activity is inhibited by oxi-
dized phospholipids that we have further characterized as hy-
droperoxides of PC. Thus, the accumulation of PCOOH in
oxidized lipoproteins could contribute to impair the reverse
cholesterol transport and pre-dispose to the development of
atherosclerosis.
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